These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31312806)

  • 21. HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).
    Mothe B; Rosás-Umbert M; Coll P; Manzardo C; Puertas MC; Morón-López S; Llano A; Miranda C; Cedeño S; López M; Alarcón-Soto Y; Melis GG; Langohr K; Barriocanal AM; Toro J; Ruiz I; Rovira C; Carrillo A; Meulbroek M; Crook A; Wee EG; Miró JM; Clotet B; Valle M; Martinez-Picado J; Hanke T; Brander C; Moltó J;
    Front Immunol; 2020; 11():823. PubMed ID: 32435247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.
    Hu X; Valentin A; Dayton F; Kulkarni V; Alicea C; Rosati M; Chowdhury B; Gautam R; Broderick KE; Sardesai NY; Martin MA; Mullins JI; Pavlakis GN; Felber BK
    J Immunol; 2016 Nov; 197(10):3999-4013. PubMed ID: 27733554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques.
    Hu X; Lu Z; Valentin A; Rosati M; Broderick KE; Sardesai NY; Marx PA; Mullins JI; Pavlakis GN; Felber BK
    Hum Vaccin Immunother; 2018; 14(9):2163-2177. PubMed ID: 29939820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
    Borthwick NJ; Lane T; Moyo N; Crook A; Shim JM; Baines I; Wee EG; Hawkins PN; Gillmore JD; Hanke T; Pepys MB
    PLoS One; 2018; 13(5):e0197299. PubMed ID: 29772028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
    Borthwick N; Ahmed T; Ondondo B; Hayes P; Rose A; Ebrahimsa U; Hayton EJ; Black A; Bridgeman A; Rosario M; Hill AV; Berrie E; Moyle S; Frahm N; Cox J; Colloca S; Nicosia A; Gilmour J; McMichael AJ; Dorrell L; Hanke T
    Mol Ther; 2014 Feb; 22(2):464-475. PubMed ID: 24166483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines.
    Wee EG; Moyo N; Hannoun Z; Giorgi EE; Korber B; Hanke T
    Mol Ther Methods Clin Dev; 2021 Jun; 21():741-753. PubMed ID: 34169114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.
    Hancock G; Yang H; Yorke E; Wainwright E; Bourne V; Frisbee A; Payne TL; Berrong M; Ferrari G; Chopera D; Hanke T; Mothe B; Brander C; McElrath MJ; McMichael A; Goonetilleke N; Tomaras GD; Frahm N; Dorrell L
    PLoS Pathog; 2015 Feb; 11(2):e1004658. PubMed ID: 25723536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth.
    Moyo N; Wee EG; Korber B; Bahl K; Falcone S; Himansu S; Wong AL; Dey AK; Feinberg M; Hanke T
    Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32640600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
    Borthwick N; Lin Z; Akahoshi T; Llano A; Silva-Arrieta S; Ahmed T; Dorrell L; Brander C; Murakoshi H; Takiguchi M; Hanke T
    PLoS One; 2017; 12(4):e0176418. PubMed ID: 28448594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.
    Ternette N; Block PD; Sánchez-Bernabéu Á; Borthwick N; Pappalardo E; Abdul-Jawad S; Ondondo B; Charles PD; Dorrell L; Kessler BM; Hanke T
    J Virol; 2015 Jun; 89(11):5760-71. PubMed ID: 25810538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
    Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.
    Munusamy Ponnan S; Pattabiram S; Thiruvengadam K; Goyal R; Singla N; Mukherjee J; Chatrath S; Bergin P; T Kopycinski J; Gilmour J; Kumar S; Muthu M; Subramaniam S; Swaminathan S; Prasad Tripathy S; Luke HE
    PLoS One; 2019; 14(3):e0213911. PubMed ID: 30921340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
    Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Immunogen Selectively Eliciting CD8
    Ishii H; Terahara K; Nomura T; Takeda A; Okazaki M; Yamamoto H; Tokusumi T; Shu T; Matano T
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32024773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.